Multimillion Dollar Costs Predicted in Screening Mammography Litigation

News
Article
OncologyONCOLOGY Vol 16 No 12
Volume 16
Issue 12

In just 10 years, the cost of screening mammography litigation in the United States could top $250 million a year, a recent analysis has found. The analysis, presented at this year’s American Roentgen Ray Society meeting in Atlanta, is based on a

In just 10 years, the cost of screening mammography litigation in the United States could top $250 million a year, a recent analysis has found. The analysis, presented at this year’s American Roentgen Ray Society meeting in Atlanta, is based on a statistical model that reviewed the number of women likely to be undergoing mammograms, the potential for missed cancers, the average lawsuit settlement ($200,000 based on 1995 figures), and other similar factors.

"We are looking at a potential medical-legalmeltdown," said Richard Tello, md, msme, mph, professor of radiology,epidemiology, and biostatistics at Boston University. The baby boomers aregetting older, so the number of women needing mammograms is going up. As moremammograms are done, the potential for missed cancers increases, leading to anincreased chance of litigation.

Conservative Calculations

"We were conservative in our calculations—assumingthat only 1 in 10 women who are litigation candidates will sue, that half of thewomen who sue will have a lesion on a previous mammogram that was missed, andthat half of this subset will actually win their case," Dr. Tello said."These litigation costs could potentially go even higher," he added.

"The analysis found that $70 per woman per mammogram(assuming that about half of eligible women would have 20 mammograms over theirlifetimes) would need to be saved beginning now, to pay these futurecosts," Dr. Tello said. "The $70 figure is based on conservativeestimates; using less conservative estimates, we found that the amount neededcould be as high as $200 per woman per mammogram."

This is a major problem, because some insurance reimbursementfor mammograms is just at or near the $70 level, Dr. Tello explained. At thisrate, it is not economically feasible for radiologists to contribute to alitigation pool. It is unlikely that insurance companies will pay more toprepare for future litigation costs. Malpractice insurance companies wouldlikely increase their premiums as litigation costs go up, making it lessattractive for radiologists to even do screening mammgraphy, he noted.

One Solution

In addition, it is unlikely that the patient will payout-of-pocket to support a litigation pool, Dr. Tello said. A solution, however,could be a federally sponsored litigation pool similar to the one that currentlyexists for vaccine lawsuits.

"The study indicates that we need to act now to avoid acrisis in 10 years, when the costs of litigation force the shutdown ofmammography facilities nationwide," he said.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Related Content